HAMPTON, N.J. , May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020 . “Despite the ongoing challenges associated with the COVID-19 pandemic, Celldex continued to make considerable

HAMPTON, N.J. , May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI)

HAMPTON, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019 . “We are pleased that Celldex entered 2020 with significant momentum, following exciting data in late

Celldex also eligible to receive future milestone payments plus royalties HAMPTON, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement with Rockefeller

CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study HAMPTON, N.J. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers.

HAMPTON, N.J. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019 . “Celldex achieved a significant milestone last week, reporting data at SITC that CDX-1140 has exceeded the

-CDX-0159 IND accepted; Phase 1 study to start by YE 2019- -CDX-527 on track for IND filing in 1H 2020- HAMPTON, N.J. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX)  presented data from the Company’s preclinical pipeline this weekend.

-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study- -Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity- -Clinical trial collaboration with Merck announced to evaluate CDX-1140 with KEYTRUDA®- HAMPTON, N.J. , Nov.

HAMPTON, N.J. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences. Society for Immunotherapy of Cancer ( SITC ) 34th Annual

HAMPTON, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci , Co-founder, President and Chief Executive Officer, and Tibor Keler , PhD, Cofounder, Executive Vice President and Chief Scientific Officer, will present a corporate